Thirty-one patients with lung cancer were entered in a weekly phase II trial of iv pyrazofurin (PZF). Dose-limiting side effects included mucositis and hematologic toxicity primarily manifested as anemia. Major therapeutic activity did not occur in the patients entered in this trial. The authors conclude that PZF has little therapeutic value as a single agent in this dose schedule in previously treated patients with advanced lung cancer. Although this trial was conducted on pretreated patients, their general condition permitted outpatient management. In addition, the median survival time of the group from the beginning of therapy was 5 months which is comparable to the survival time in some groups receiving initial chemotherapy.
|Original language||English (US)|
|Number of pages||2|
|Journal||Cancer Treatment Reports|
|Publication status||Published - Dec 1 1978|
ASJC Scopus subject areas
- Cancer Research